Fat and the Heart: A More and More Complex Interplay

Stefan Dhein

doi:10.1055/s-0034-1377064

The Thoracic and Cardiovascular Surgeon, Inhaltsverzeichnis

Thorac Cardiovasc Surg 2014; 62(07): 543-546
DOI: 10.1055/s-0034-1377064

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

Fat and the Heart: A More and More Complex Interplay

Stefan Dhein

¹Clinic for Cardiac Surgery, Heart Center Leipzig, University Leipzig, Leipzig, Germany

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Volltext

Referenzen

References
1 Sumeray M, Steiner M, Sutton P, Treasure T. Age and obesity as risk factors in perioperative atrial fibrillation. Lancet 1988; 2 (8608) 448
2 Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112 (21) 3247-3255
3 Lin Y-K, Chen Y-C, Chen J-H, Chen SA, Chen YJ. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol 2012; 107 (5) 293
4 Wang TJ, Parise H, Levy D , et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292 (20) 2471-2477
5 Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005; 118 (5) 489-495
6 Boldt A, Wetzel U, Lauschke J , et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90 (4) 400-405
7 Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999; 85 (5) 428-436
8 Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012; 33 (15) 1870-1877
9 Greiser M, Schotten U. Dynamic remodeling of intracellular Ca²⁺ signaling during atrial fibrillation. J Mol Cell Cardiol 2013; 58: 134-142
10 Brundel BJJM, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002; 54 (2) 315-324
11 Polontchouk L, Haefliger J-A, Ebelt B , et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38 (3) 883-891
12 Dhein S, Rothe S, Busch A , et al. Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation. Br J Pharmacol 2011; 164 (2b) 607-616
13 Hernández-Romero D, Jover E, Marín F , et al. The prognostic role of the adiponectin levels in atrial fibrillation. Eur J Clin Invest 2013; 43 (2) 168-173
14 Rienstra M, Sun JX, Lubitz SA , et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012; 163 (1) 119-124 , e1
15 Shimano M, Shibata R, Tsuji Y , et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008; 72 (7) 1120-1124
16 Rothe S, Busch A, Bittner H , et al. Body mass index affects connexin43 remodeling in patients with atrial fibrillation. Thorac Cardiovasc Surg 2014; 62 (7) 547-553
17 Tadic M, Ivanovic B, Bradic Z , et al. The influence of the metabolic syndrome on atrial fibrillation occurrence and outcome after coronary bypass surgery: a 3-year follow-up study. Thorac Cardiovasc Surg 2014; 62 (7) 561-568
18 Rachwalik M, Zysko D, Diakowska D , et al. Increased content of resistin in pericardial adipose tissue of patients with advanced atherosclerosis and a history of myocardial infarction. Thorac Cardiovasc Surg 2014; 62 (7) 554-560
19 Northcott JM, Yeganeh A, Taylor CG , et al. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol 2012; 90: 1029-1059
20 Greulich S, Chen WJ, Maxhera B , et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS ONE 2013; 8 (3) e59697
21 Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012; 6 (2) 120-124
22 Xiao J, Sun B, Li M, Wu Y, Sun XB. A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease. J Cell Physiol 2013; 228 (3) 495-501
23 Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011; 129 (2) 206-219
24 Li H, Peng W, Zhuang J , et al. Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-κB signaling pathways. Atherosclerosis 2013; 228 (1) 61-68
25 Hida K, Wada J, Eguchi J , et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005; 102 (30) 10610-10615
26 Csaki LS, Dwyer JR, Fong LG, Tontonoz P, Young SG, Reue K. Lipins, lipinopathies, and the modulation of cellular lipid storage and signaling. Prog Lipid Res 2013; 52 (3) 305-316
27 Miner JL. The adipocyte as an endocrine cell. J Anim Sci 2004; 82 (3) 935-941
28 Sniderman AD, Cianflone K. The adipsin-ASP pathway and regulation of adipocyte function. Ann Med 1994; 26 (6) 388-393